Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14168364 | 1.00 | MAOA (0.38) | MAOAIRAK4MAPK1L3MBTL1PTPN1 | |
| SCHEMBL9230345 | 0.81 | MAPK1 (0.49) | MAOAMAPK1L3MBTL1PTPN1ACP1 | |
| SCHEMBL9230346 | 0.80 | HTR2B (0.41) | MAOAMAPK1L3MBTL1GRM2 | |
| SCHEMBL9230342 | 0.80 | HTR2B (0.41) | MAOAMAPK1L3MBTL1GRM2 | |
| SCHEMBL10368362 | 0.80 | CA2 (0.47) | MAOAMAPK1L3MBTL1GRM2 | |
| SCHEMBL14183559 | 0.80 | CA2 (0.47) | MAOAMAPK1L3MBTL1GRM2 | |
| SCHEMBL16609887 | 0.79 | MAOA (0.57) | MAOAIRAK4MAPK1L3MBTL1GRM2 | |
| SCHEMBL10600802 | 0.78 | CYP2D6 (0.49) | IRAK4MAPK1L3MBTL1GRM2 | |
| SCHEMBL17824144 | 0.78 | CYP2D6 (0.49) | IRAK4MAPK1L3MBTL1GRM2 | |
| SCHEMBL17823617 | 0.78 | CYP2D6 (0.49) | IRAK4MAPK1L3MBTL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785625-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | SUZUKI HIDEYUKI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAOA 2965/4885IRAK4 2233/4885MAPK1 3023/4885 |
| US-20120208997-A1 | NOVEL COMPOUND HAVING HETEROCYCLIC RING | OXA1L, MRPL21, TOP1 | MAOA 1563/4885IRAK4 772/4885MAPK1 2114/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MAOA 2966/4885IRAK4 2094/4885MAPK1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.